RESUMO
This review highlights the underexplored potential and promises of marine bioactive peptides (MBPs) with unique structural, physicochemical, and biological activities to fight against the current and future human pathologies. A particular focus is given to the marine environment as a significant source to obtain or extract high-value MBPs from touched/untouched sources. For instance, marine microorganisms, including microalgae, bacteria, fungi, and marine polysaccharides, are considered prolific sources of amino acids at large, and peptides/polypeptides in particular, with fundamental structural sequence and functional entities of a carboxyl group, amine, hydrogen, and a variety of R groups. Thus, MBPs with tunable features, both structural and functional entities, along with bioactive traits of clinical and therapeutic value, are of ultimate interest to reinforce biomedical settings in the 21st century. On the other front, as the largest biome globally, the marine biome is the so-called "epitome of untouched or underexploited natural resources" and a considerable source with significant potentialities. Therefore, considering their biological and biomedical importance, researchers around the globe are redirecting and/or regaining their interests in valorizing the marine biome-based MBPs. This review focuses on the widespread bioactivities of MBPs, FDA-approved MBPs in the market, sustainable development goals (SDGs), and legislation to valorize marine biome to underlying the impact role of bioactive elements with the related pathways. Finally, a detailed overview of current challenges, conclusions, and future perspectives is also given to satisfy the stimulating demands of the pharmaceutical sector of the modern world.
Assuntos
Organismos Aquáticos , Produtos Biológicos , Peptídeos , Animais , Produtos Biológicos/farmacologia , Produtos Biológicos/uso terapêutico , Aprovação de Drogas , Ecossistema , Humanos , Peptídeos/farmacologia , Peptídeos/uso terapêutico , Desenvolvimento Sustentável , Estados Unidos , United States Food and Drug AdministrationRESUMO
Naturally occurring biological entities with extractable and tunable structural and functional characteristics, along with therapeutic attributes, are of supreme interest for strengthening the twenty-first-century biomedical settings. Irrespective of ongoing technological and clinical advancement, traditional medicinal practices to address and manage inflammatory bowel disease (IBD) are inefficient and the effect of the administered therapeutic cues is limited. The reasonable immune response or invasion should also be circumvented for successful clinical translation of engineered cues as highly efficient and robust bioactive entities. In this context, research is underway worldwide, and researchers have redirected or regained their interests in valorizing the naturally occurring biological entities/resources, for example, algal biome so-called "treasure of untouched or underexploited sources". Algal biome from the marine environment is an immense source of excellence that has also been demonstrated as a source of bioactive compounds with unique chemical, structural, and functional features. Moreover, the molecular modeling and synthesis of new drugs based on marine-derived therapeutic and biological cues can show greater efficacy and specificity for the therapeutics. Herein, an effort has been made to cover the existing literature gap on the exploitation of naturally occurring biological entities/resources to address and efficiently manage IBD. Following a brief background study, a focus was given to design characteristics, performance evaluation of engineered cues, and point-of-care IBD therapeutics of diverse bioactive compounds from the algal biome. Noteworthy potentialities of marine-derived biologically active compounds have also been spotlighted to underlying the impact role of bio-active elements with the related pathways. The current review is also focused on the applied standpoint and clinical translation of marine-derived bioactive compounds. Furthermore, a detailed overview of clinical applications and future perspectives are also given in this review.
Assuntos
Anti-Inflamatórios/farmacologia , Organismos Aquáticos/metabolismo , Doenças Inflamatórias Intestinais/tratamento farmacológico , Intestinos/efeitos dos fármacos , Animais , Anti-Inflamatórios/isolamento & purificação , Humanos , Mediadores da Inflamação/metabolismo , Doenças Inflamatórias Intestinais/imunologia , Doenças Inflamatórias Intestinais/metabolismo , Doenças Inflamatórias Intestinais/patologia , Intestinos/imunologia , Intestinos/patologia , Transdução de SinaisRESUMO
This study signifies the rich pharmacological potential of Hibiscus sabdariffa, exploring its bioactive components and their therapeutic implications for health and wellness. Despite the promising insights, a comprehensive critical analysis is essential to ensure scientific rigour. To address this, the study establishes clear aims and objectives, aiming to scrutinise the study findings through a meticulous assessment. In conclusion, this study, upon addressing these key points, aspires to offer a robust contribution to scientific research, by advancing the understanding of H. sabdariffa's therapeutic attributes and promoting the adoption of sustainable methodologies in scientific research.
Assuntos
Hibiscus , Extratos Vegetais , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêuticoRESUMO
BACKGROUND: In Indian traditional medicine, the Abutilon indicum plant, colloquially known as "Country mallow" or "Thuthi", has been vouched for its efficacy in treating conditions such as bronchitis and diabetes. The study aimed to explore the chemical constituents and antioxidant strength of the ethanolic extracts derived from the leaves of this plant (ELEAI). OBJECTIVES: To qualitatively pinpoint the phytochemicals in the ethanolic extract of abutilon indicum leaves (ELEAI), utilize high-performance thin layer chromatography (HPTLC) to quantitatively analyze the identified compounds within the ELEAI, and gauge its antioxidant capability through the DPPH method, benchmarking the outcomes against the recognized standard, ascorbic acid. METHODS: Abutilon indicum leaves, originating from Telangana, were authenticated by taxonomists at Osmania University. After cleaning and drying, the leaves were powdered. A mixture of ethanol and water (70:30 ratio) was then used to extract the compounds in a Soxhlet extractor for a duration of 72 hours at a temperature of 60°C. The liquid extract was subsequently evaporated to form a light-brown powder, which was stored at 20°C under shade for later use. RESULTS: Preliminary analyses indicated that ELEAI was rich in both primary and secondary metabolites. Luteolin, a known phytochemical, was quantitatively confirmed in the extract using HPTLC. Impressively, the DPPH assay highlighted ELEAI's remarkable antioxidant capabilities. CONCLUSION: Abutilon indicum showcases notable therapeutic potential with its rich phytochemical content and strong antioxidant activity, making it a promising candidate for further pharmacological research and natural drug formulation.